Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Watch it bounce up from here!
My answer to sage was quoting back what they had said on 26 Jan
You are generally right hunky monkey. Fortunately I’m not reliant on my isa and sipp and my wife’s pension and sipp aren’t at risk. I already have a service pension and war pension and the house is paid off so my money my risk! Hence not advice for anyone else to follow!
Sage
I think it’s a great opportunity and believe in it wholeheartedly medium - long term.
I’ve gone all in with my isa and Sipp. Happy to take the risk. GLA
DTW thanks. I’ve also added a few more to my holding today and happy to wait now. GL
Just to add - they also stated in another answer that the Phase 2 study was expected to begin in 2H24 so 🤞IMHO ‘pivotal’ SP news will be released before that. GLA
That’s a lot of money RMFatGB!
Just been reading through some of the Q&A on the presentation of 13th Dec. & this answer stood out
Please note: We cannot provide specific details of ongoing business development discussions not only because this is inappropriate from a market sensitive information perspective but also because it would actually jeopardise these potential relationships. The high level commercial strategy was set out at the AGM in June 2023; this strategy has not changed. (For reference, slide 11 here: https://avacta.com/wp-content/uploads/2023/06/Avacta-AGM-2023-presentations.pdf). The Company has the opportunity to commercialise both its specific assets, such as AVA6000 or AVA3996, and its platform technologies - pre|CISION and Affimer. It is strategically important for the company to continue to wholly own its lead clinical programme – AVA6000 – for now. Taking this asset into phase 2 not only adds value for shareholders by generating efficacy data but also maintains Avacta’s clinical stage status which is important for attracting specialist healthcare investors. Avacta therefore plans to take AVA6000 into phase 2 and will then consider partnering this asset to take it to market and to broaden its applications into other cancer indications. There is potential to partner AVA3996 or any other undisclosed pipeline assets at a preclinical stage. More importantly in the short term is the potential to partner the pre|CISION platform. This means potentially licensing the platform to a third party to use in combination with their own cytotoxic agent. Such a licensing deal would be expected to be narrowly focused on a specific agent or agents. The clinical data published on December 13th 2023 plays a pivotal role in generating business development discussions and accelerating those that are ongoing.
So the appointment of Dr Simon ‘to accelerate ongoing discussions’ on 19th Dec should hopefully result in news of a partnership deal as mentioned ‘in the short term’ - before phase 2 of AVA6000
Toatie I’m fairly sure they mentioned it in answer to shareholders questions on the investor meet website https://www.investormeetcompany.com/avacta-group-plc
Nice that the employees are getting rewarded.
I’d be surprised if we weren’t in negotiation with other company’s after the Appointment by Avacta of Dr Simon Bennett as Chief Business Officer of the Therapeutics Division. Which they said ‘signals commercial emphasis for Avacta to leverage clinical progress’. No doubt he is ‘just getting on with it’ but let’s hope we hear news soon! GLA
“The efficacy and side effects are therefore significantly improved." 🤔 could well be us?
No trades today? Is this the bottom? Anyone got sight of bid / offer - level 2?
Hi Share-ke I would think it is a possibility at the rate the BoD are going. Not enough sales to be profitable and too heavy with salaries. However against that is the small market cap and the possibility of a TO from big Pharma. Much more likely than either of those two scenarios is a cash raise and drift further downwards in the absence of much more positive actions from the BoD rather than relying on peer to peer sales - which haven’t proved to be effective as yet (a change of direction which has not yet demonstrated and the recent meeting didn’t inspire confidence).
FWIW my advice is don’t keep any money in here unless you are willing to lose it. For clarity as I posted when I invested here I’ve just crystallised a small loss here as another share I own indicates it is a better bet for these funds. GLA
What the company has to do is look at the costs of those unnecessary procedures currently being carried out due to the current inaccurate screening measures and demonstrate PSE testing is overall cost effective for the NHS
Interesting interview posted on the Avacta chat group.
Https://www.youtube.com/watch?v=Rdk7az1bdqo&t=2030s
They discuss Avacta at 33 mins but go on straight after that to discuss OBD which gives an insight into why a fund manager sold their position in OBD and might indicate that they could be waiting to buy back in here? Especially when it seems the SP has bottomed out ? Which could provide an added lift? GLA
Griffiths_I - interesting interview particularly as they go on to discuss another share I’m invested in straight after Avacta at 38 mins.
Didn’t even notice the typo krull - must be my dyslexia (at least it worked in my favour that time!)
I bought back in and am holding for the same reason Kingalf. I’d have been happier if the SP had kept going back up when I identified it bouncing up earlier (but might have been that famous ‘dead cat’? 🐈⬛ 🤨). GL
Dugwalker we must also be ripe for a hostile takeover surely? PI’s would snatch the hand off any reasonable offer or attempt to oust the board 🤨
Pensioninvestor it’s always better to spread your risk and plenty of other shares with at least as good prospects (Avacta Alpha to name two) but this isn’t investment advice DYOR. Accept shares are a gamble whatever you decide - but wider investment spreads the risk. Good luck to you.